Delcath Systems (NSDQ:DCTH) has raised $2 million after selling 2,360 shares of Series B preferred stock at $1,000 per share to unnamed institutional investors, according to a regulatory filing. The company wrote that it plans to use the proceeds for general corporate purposes. Delcath is developing a system for liver-directed high dose chemotherapy, which involves a […]
Featured
Eli Lilly pledges up to $52m to Purdue for improving injection tech
Eli Lilly (NYSE:LLY) said today that it pledged up to $52 million to Purdue University as part of a 5-year research agreement. The deal is Purdue’s largest strategic collaboration with a single company, according to the university. The group is slated to focus on improving the delivery of injectable medications with the goals of reducing pain and […]
Novo Nordisk recalls cartridge holders in insulin delivery devices
Novo Nordisk (NYSE:NVO) launched a recall yesterday of insulin cartridge holders used in select batches of NovoPen Echo insulin delivery devices. The company said the cartridge holders could crack or break upon exposure to certain chemicals. Using a NovoPen Echo with a cracked or broken cartridge holder could result in the device delivering a lower dose […]
Oramed to dual-list on Tel Aviv exchange
Oramed Pharmaceuticals (NSDQ:ORMP) said today that it won approval from the Israel Securities Authority to dual-list its common stock on the Tel Aviv Stock Exchange. Stock in the Jerusalem-based company is slated to begin trading on the TASE on July 12 under the symbol ‘ORMP’. “We believe dual-listing on the TASE will provide many benefits […]
Aequus to launch trial for anti-nausea patch
Aequus Pharmaceuticals (CVE:AQS) said today that it won approval from Health Canada to launch a proof-of-concept trial to evaluate the bioavailability and safety of the company’s long-acting transdermal anti-nausea patch. The device is made up of a combination of pyridoxine and doxylamine. The traditional form is delivered orally up to 4 times per day. The […]
‘Nanolock’ could help diagnose and treat cancer with individualized therapies
In a study published in ACS Sensors, a team of researchers described how they develop a method to recognize a particular mutation in the genetic code of a cancerous cell. If cancers are caught early enough in the cell mutation process, many of them can be stopped with chemotherapy and other forms of treatment. This new […]
Diasome lands $30m to fund clinical trials of liver-targeted insulin
Diasome Pharmaceuticals said today that it inked a funding deal that could bring the company up to $30 million. The round was led by Medicxi and contributed to by JDRF T1D Fund, Black Beret Life Sciences and McDonald Partners. The Cleveland-based company said it plans to use the funds to support the clinical development of […]
SICPA aims to arm companies against counterfeit drugs, devices
Counterfeit drugs and medical devices are a pervasive problem for the pharmaceutical industry and for consumers. It’s an issue that affects countries around the world, according to SICPA, a firm that has developed secured identification and traceability solutions for companies to assess and manage risks to their products. “In places like Sub-Saharan Africa, 30-40% of […]
Antibody could be first new mechanism of action for HIV treatment in 10 years
Theratechnologies (TSE:TH) said today that the FDA granted priority review to the biologics license application for ibalizumab as a treatment for multi-drug resistant HIV-1. If the monoclonal antibody is approved, it will be the first antiretroviral treatment with a new mechanism of action to be introduced in a decade. It would also be the only […]
Novo Nordisk touts late-stage trial data for Tresiba insulin injection
Novo Nordisk (NYSE:NVO) touted data today from 2 Phase IIIb trials comparing Tresiba insulin degludec to insulin glargine in adults with Type I and Type II diabetes. The results were published in the Journal of the American Medical Association. The Switch trials are the 1st double-blinded insulin trials to compare the hypoglycemia rates and risks in patients […]